Calcitonin Pre-treatment to Improve SPECT-CT Sensitivity

Summary

Patients with biochemically confirmed primary hyperparathyroidism and non-localizing SPECT-CT exam within the past year will be included. Subjects will be treated with calcitonin to lower calcium levels immediately prior to reimaging. The goal of this study is to determine whether lowering calcium will improve uptake/retention of sestamibi and improve sensitivity of SPECT-CT to localize parathyroid adenoma.

Timeline

Start

2019-05-29

Primary completion

2026-06-01

Completion

2026-12-31

Drugs

Indications